MENU
+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Apr 2, 10:43 AM (EDT)
Price
$26.84
Change
-$0.17 (-0.63%)
Net Assets
81.98M

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SBIO with price predictions
Apr 01, 2025

SBIO's Indicator enters downward trend

The Aroon Indicator for SBIO entered a downward trend on March 13, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 218 similar instances where the Aroon Indicator formed such a pattern. In of the 218 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SBIO turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

SBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 1.71B. The market cap for tickers in the group ranges from 55.89M to 13.87B. SMMT holds the highest valuation in this group at 13.87B. The lowest valued company is INZY at 55.89M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 52%. For the same ETF, the average monthly price growth was 56%, and the average quarterly price growth was 91%. CORT experienced the highest price growth at 58%, while PCVX experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 94%. For the same stocks of the ETF, the average monthly volume growth was 13% and the average quarterly volume growth was 146%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 77
Price Growth Rating: 70
SMR Rating: 89
Profit Risk Rating: 84
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com